Search results for "Advanced fibrosis"

showing 5 items of 5 documents

Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis

2021

[Background and Aims] Vibration-controlled transient elastography (VCTE), point shear wave elastography (pSWE), 2-dimensional shear wave elastography (2DSWE), magnetic resonance elastography (MRE), and magnetic resonance imaging (MRI) have been proposed as non-invasive tests for patients with non-alcoholic fatty liver disease (NAFLD). This study evaluated their diagnostic accuracy for liver fibrosis and non-alcoholic steatohepatitis (NASH).

0301 basic medicineFIBROSIS NONINVASIVE ASSESSMENTCirrhosisTransient elastographydeMILI0302 clinical medicineMedicineBARIATRIC SURGERY CANDIDATESNon-alcoholic steatohepatitismedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISFatty liverMagnetic Resonance Imaging3. Good healthArea Under CurveLiver biopsyElasticity Imaging TechniquesNASH-MRI030211 gastroenterology & hepatologyBio-markersRadiologyElastographyDiffusion-weighted imagingLife Sciences & BiomedicineAdultPREDICTS ADVANCED FIBROSISmedicine.medical_specialtyBiomarkers deMILI Diffusion-weighted imaging Magnetic resonance elastography NASH-MRI Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis Shear wave elastography Transient elastography AdultArea Under Curve Elasticity Imaging Techniques Humans Magnetic Resonance Imaging Non-alcoholic Fatty Liver Disease ROC Curve fibro-MRI Iron-corrected T1 Liver fibrosisLiver fibrosisCONTROLLED ATTENUATION PARAMETERSTIFFNESS MEASUREMENT03 medical and health sciencesIron-corrected T1HumansFATTY LIVER-DISEASEScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryRADIATION FORCE IMPULSEMagnetic resonance imagingmedicine.diseaseCONTROLLED TRANSIENT ELASTOGRAPHYMagnetic resonance elastography030104 developmental biologyROC CurveMagnetic resonance elastographyShear wave elastographyXL PROBEHuman medicinefibro-MRISteatohepatitisbusinessTransient elastographyBiomarkersNon-alcoholic fatty liver diseaseJournal of Hepatology
researchProduct

Refining Noninvasive Diagnostics In Nonalcoholic Fatty Liver Disease: Closing the Gap to Detect Advanced Fibrosis

2019

Liver Cirrhosismedicine.medical_specialtyHepatologybusiness.industryComplement C3medicine.diseaseGastroenterologyAdvanced fibrosisLiverNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseasemedicineHumansClosing (morphology)businessAlgorithmsHepatology
researchProduct

Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease.

2019

Background & Aim There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced disease and identify patients suitable for clinical trials. The PRO-C3 collagen neo-epitope is a putative direct marker of fibrogenesis. We assessed the performance of PRO-C3 in a large, well-characterised international NAFLD cohort and report the development and validation of 2 novel panels for the diagnosis of advanced fibrosis (F≥3) in NAFLD, including a simplified clinical score which eliminates the need for online calculators. Methods Plasma PRO-C3 levels were determined in a prospectively recruited international cohort of 449 patients with biopsy …

medicine.medical_specialtyADVANCED FIBROSISSCORING SYSTEMPROGRESSIONGastroenterologySTEATOHEPATITIS03 medical and health sciences0302 clinical medicineFibrosisInternal medicineNAFLDBiopsyInternal MedicineImmunology and AllergyMedicineSTEATOSISPRO-C3Stage (cooking)lcsh:RC799-869030304 developmental biologySteatohepatitisRISK0303 health sciencesScience & TechnologyHepatologymedicine.diagnostic_testGastroenterology & Hepatologybusiness.industryFatty liverfibrosisGastroenterologyNASHDIABETES-MELLITUSCHRONIC HEPATITISBiomarkermedicine.disease3. Good healthClinical trialCohortBIOPSYBiomarker (medicine)030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. GastroenterologySteatohepatitisbusinessLife Sciences & BiomedicineResearch ArticleJHEP reports : innovation in hepatology
researchProduct

Efficacy and safety of Boceprevir-based therapy in HCVG1 treatment-experienced patients with advanced fibrosis/cirrhosis: Italian NPP survey

2014

S. Bruno1, S. Bollani1, A.L. Zignego2, V. Calvaruso3, C. Magni4, S. Landonio4, M. Rizzetto5, A. Ciancio5, A. Mangia6, V. Piazzolla6, M. Caremani7, S. Piovesan8, L. Cavalletto9, S. Babudieri9, A. Moretti 10, C. Colletta11, M. Massari12, S. Fangazio13, F. Mazzotta14, L. Muratori15, A.E. Colombo16, M. Zuin17, A. Traverso18, T. Santantonio19, F. Farina20, E. Marchionne21, G. Serviddio22, M. Russello23, A. Licata24, A. Craxi3, V. Di Marco3 1 Internal Medicine, AO Fatebenefratelli e Oftalmico, Milano, Italy 2 Internal Medicine, Universita di Firenze, Italy 3 Gastroenterology, Universita di Palermo, Italy 4 Infectiuos Diseases, Ospedale Sacco, Milano, Italy 5 Gastroenterology, Universita di Torino…

medicine.medical_specialtyHepatologybusiness.industryInfectious disease (medical specialty)Family medicineGastroenterologymedicinebusinessTreatment experiencedAdvanced fibrosisDigestive and Liver Disease
researchProduct

Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice.

2020

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) prevalence has increased in the past two decades, resulting in a significant but under-recognised public health burden. This impacts the prevalence of advanced fibrosis, end-stage liver disease and associated extrahepatic manifestations. To understand the challenges in recognising patients with advanced fibrosis due to NASH and develop a standardised approach to screen these patients, the authors of this document provided their opinions and expertise from practice and published evidence to identify key challenges and current approaches for diagnosing NASH. The severity of liver fibrosis due to NASH is the main …

Liver Cirrhosismedicine.medical_specialtyBest practicePsychological interventionMEDLINEDiseasedigestive systemRisk Assessment03 medical and health sciencesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNonalcoholic fatty liver diseasemedicineHumansMass ScreeningIntensive care medicinebusiness.industryPublic healthGastroenterologymedicine.diseaseAdvanced fibrosis Best practice Identification NAFLD NASHdigestive system diseasesEarly Diagnosis030220 oncology & carcinogenesisPractice Guidelines as TopicDisease Progression030211 gastroenterology & hepatologyIdentification (biology)businessAlgorithmsJournal of gastrointestinal and liver diseases : JGLD
researchProduct